For research use only. Not for therapeutic Use.
Moxidectin（Cat No.:I000507）is an antiparasitic medication used to treat river blindness (onchocerciasis) and other parasitic infections, such as scabies and strongyloidiasis. It works by binding to glutamate-gated chloride channels in parasitic worms, leading to paralysis and death of the parasite. Moxidectin is highly effective against Onchocerca volvulus, the parasite responsible for river blindness, and offers a long-lasting therapeutic effect compared to other treatments. Its ability to kill both larval and adult stages of parasites makes it a valuable tool in controlling and reducing the prevalence of parasitic diseases, particularly in endemic regions.
| Catalog Number | I000507 |
| CAS Number | 113507-06-5 |
| Synonyms | CL-301423 |
| Molecular Formula | C37H53NO8 |
| Purity | 98% |
| Target | Onchoc GluCl |
| Target Protein | Q25634 |
| Solubility | DMSO:40mg/mL |
| Appearance | Solid |
| Storage | Dry, dark and at 2 - 8 °C for six months or -20°C for two years. |
| IUPAC Name | (1R,4S,4'E,5'S,6R,6'S,8R,10E,13R,14E,16E,20R,21R,24S)-21,24-dihydroxy-4'-methoxyimino-5',11,13,22-tetramethyl-6'-[(E)-4-methylpent-2-en-2-yl]spiro[3,7,19-trioxatetracyclo[15.6.1.14,8.020,24]pentacosa-10,14,16,22-tetraene-6,2'-oxane]-2-one |
| InChI | InChI=1S/C37H53NO8/c1-21(2)14-25(6)33-26(7)31(38-42-8)19-36(46-33)18-29-17-28(45-36)13-12-23(4)15-22(3)10-9-11-27-20-43-34-32(39)24(5)16-30(35(40)44-29)37(27,34)41/h9-12,14,16,21-22,26,28-30,32-34,39,41H,13,15,17-20H2,1-8H3/b10-9+,23-12+,25-14+,27-11+,38-31+/t22-,26-,28+,29-,30-,32+,33+,34+,36-,37+/m0/s1 |
| InChIKey | YZBLFMPOMVTDJY-LSGXYNIPSA-N |
| SMILES | C[C@@H]\1C/C(=C/C[C@@H]2C[C@@H](C[C@@]3(O2)C/C(=N\OC)/[C@@H]([C@H](O3)/C(=C/C(C)C)/C)C)OC(=O)[C@@H]4C=C([C@H]([C@@H]5[C@]4(/C(=C/C=C1)/CO5)O)O)C)/C |
| Reference | </br>1:Efficacy of moxidectin versus ivermectin against Strongyloides stercoralis infections: a randomized controlled non-inferiority trial. Barda B, Sayasone S, Phongluxa K, Xayavong S, Keoduangsy K, Odermatt P, Puchkov M, Huwyler J, Hattendorf J, Keiser J.Clin Infect Dis. 2017 Mar 25. doi: 10.1093/cid/cix278. [Epub ahead of print] PMID: 28369530 </br>2:A multi-country study to assess the effect of a treatment with moxidectin pour-on during the dry period on milk production in dairy cows. Geurden T, Bartram DJ, Vanimisetti HB, Fanke J, Camuset P, Devos J, Sawyer A, von Samson-Himmelstjerna G, Demeler J, Charlier J.Vet Parasitol. 2017 Apr 15;237:104-109. doi: 10.1016/j.vetpar.2017.02.010. Epub 2017 Feb 20. PMID: 28259556 </br>3:Strongyle egg reappearance period after moxidectin treatment and its relationship with management factors in UK equine populations. Tzelos T, Barbeito JS, Nielsen MK, Morgan ER, Hodgkinson JE, Matthews JB.Vet Parasitol. 2017 Apr 15;237:70-76. doi: 10.1016/j.vetpar.2017.02.018. Epub 2017 Feb 21. PMID: 28249767 </br>4:Shortened egg reappearance after ivermectin or moxidectin use in horses in the UK. Daniels SP, Proudman CJ.Vet J. 2016 Dec;218:36-39. doi: 10.1016/j.tvjl.2016.11.003. Epub 2016 Nov 14. PMID: 27938707 </br>5:Efficacy and duration of action of oral fluralaner and spot-on moxidectin/imidacloprid in cats infested with Lynxacarus radovskyi. Han HS, Noli C, Cena T.Vet Dermatol. 2016 Dec;27(6):474-e127. doi: 10.1111/vde.12390. PMID: 27870235 </br>6:The Anthelmintic Ingredient Moxidectin Negatively Affects Seed Germination of Three Temperate Grassland Species. Eichberg C, Wohde M, Müller K, Rausch A, Scherrmann C, Scheuren T, Düring RA, Donath TW.PLoS One. 2016 Nov 15;11(11):e0166366. doi: 10.1371/journal.pone.0166366. eCollection 2016. PMID: 27846249 Free PMC Article</br>7:Preclinical development of moxidectin as a novel therapeutic for alcohol use disorder. Huynh N, Arabian N, Naito A, Louie S, Jakowec MW, Asatryan L, Davies DL.Neuropharmacology. 2017 Feb;113(Pt A):60-70. doi: 10.1016/j.neuropharm.2016.09.016. Epub 2016 Sep 15. PMID: 27641072 </br>8:A green alternative method for analysis of ivermectin and moxidectin in environmental water samples using automatized preconcentration previous MEEKC. Felici E, Casado C, Wang CC, Raba J, Gomez MR.Electrophoresis. 2016 Nov;37(22):2977-2985. doi: 10.1002/elps.201600303. Epub 2016 Oct 25. PMID: 27649642 </br>9:Preclinical Study of Single-Dose Moxidectin, a New Oral Treatment for Scabies: Efficacy, Safety, and Pharmacokinetics Compared to Two-Dose Ivermectin in a Porcine Model. Bernigaud C, Fang F, Fischer K, Lespine A, Aho LS, Dreau D, Kelly A, Sutra JF, Moreau F, Lilin T, Botterel F, Guillot J, Chosidow O.PLoS Negl Trop Dis. 2016 Oct 12;10(10):e0005030. doi: 10.1371/journal.pntd.0005030. eCollection 2016 Oct. PMID: 27732588 Free PMC Article</br>10:Efficacy and Safety of Moxidectin, Synriam, Synriam-Praziquantel versus Praziquantel against Schistosoma haematobium and S. mansoni Infections: A Randomized, Exploratory Phase 2 Trial. Barda B, Coulibaly JT, Puchkov M, Huwyler J, Hattendorf J, Keiser J.PLoS Negl Trop Dis. 2016 Sep 16;10(9):e0005008. doi: 10.1371/journal.pntd.0005008. eCollection 2016 Sep. PMID: 27636542 Free PMC Article |
